Navigation Links
New lymphoma therapies targets diverse and difficult cancer
Date:4/24/2008

NEW YORK (April 24, 2008) -- The fifth leading cause of cancer in the United States, lymphoma is made up of more than 40 rare and highly diverse diseases that target the body's lymphatic system. Lymphomas include both one of the fastest growing cancers -- Burkitt's lymphoma, which can double in size in as little as a day -- and one of the slowest, chronic lymphocytic leukemia (CLL).

While all lymphoma types can be cured or managed as a chronic disease, its complexity and variation do not allow for a one-size-fits-all treatment approach. Instead, it necessitates highly specialized and individualized approaches.

With a dozen new therapies in development -- one of the largest portfolios of lymphoma drugs under development anywhere -- the Herbert Irving Comprehensive Cancer Center of NewYork-Presbyterian Hospital and Columbia University Medical Center is meeting this challenge with highly effective new treatments for the disease, giving hope to the more than one million lymphoma patients worldwide.

In 2006, NewYork-Presbyterian/Columbia recruited Dr. Owen A. O'Connor, one of the world's top lymphoma researchers, to lead its Lymphoid Development and Malignancy Program, and direct more than 25 full-time scientists and physician scientists.

"By increasing the number and quality of treatment options for lymphoma patients, we are improving their chances for survival. This is especially critical for patients who haven't responded to standard therapies," says Dr. O'Connor, who is also chief of the Lymphoma Service at NewYork-Presbyterian/Columbia and associate professor of medicine at Columbia University College of Physicians and Surgeons.

One of the most promising new therapies developed at NewYork-Presbyterian/Columbia is PDX (pralatrexate) for T-cell lymphoma -- among the most fatal forms of the disease. The drug is uniquely designed to camouflage itself as a folic acid, which allows it to be absorbed by the tumor, where it attacks the cancer. The therapy has been shown effective in 54 percent of patients who did not respond to other treatments. The drug is now being evaluated around the world, and if its activity is confirmed, it may get regulatory approval some time next year.

"Our hope is that the national multi-center clinical trial that is currently underway to evaluate this drug will result in an improved treatment option for patients," says Dr. O'Connor, who has played a leading role in developing the drug.

Researchers are also exploring novel lymphoma treatments that are not chemotherapies. These include drugs targeting Bcl-6, a gene cloned by Dr. Riccardo Dalla-Favera in 1993, and an enzyme known as histone deacetylase. Work by Dr. Dalla-Favera has shown that drugs affecting these two targets will markedly synergize with conventional chemotherapy, and may lower the amount of chemotherapy necessary to achieve remission.

"We are very excited about the promise of these new therapies. Our lymphoma program includes some of the nation's brightest scientists working together to translate laboratory discoveries into improved treatment options for patients," says Dr. Dalla-Favera, who is director of the Herbert Irving Comprehensive Cancer Center at NewYork-Presbyterian/Columbia, director of the Institute of Cancer Genetics at Columbia University Medical Center and Uris Professor of Pathology and Genetics & Development at Columbia University College of Physicians and Surgeons.


'/>"/>

Contact: Jennifer Homa
jeh9057@nyp.org
212-305-5587
New York- Presbyterian Hospital/Columbia University Medical Center
Source:Eurekalert

Related medicine news :

1. The Leukemia & Lymphoma Society Hosts Workshop On Weighing Treatment Options For Chronic Myelogenous Leukemia
2. The Leukemia & Lymphoma Society Provides Patients with the Latest Information on Myeloma
3. Cell Therapeutics, Inc. (CTI) Plans to Submit Supplemental Biologics License Application (sBLA) for ZEVALIN(R) Consolidation of First Remission in Advanced Stage Follicular Lymphoma in 2008
4. January 1 Looms Large for Lymphoma Patients
5. Micromet and MedImmune to Present New Clinical Data for Anti-CD19 BiTE(R) Antibody at American Society of Hematology Annual Meeting Showing Objective Clinical Responses in Relapsed Non-Hodgkins Lymphoma Patients
6. Possible Cure for Rare Lymphoma Reported
7. Pharmion and Methylgene Report Favorable Results for Phase 2 MGCD0103 Single- Agent Studies in Relapsed or Refractory Lymphomas at the 49th American Society of Hematology (ASH) Meeting
8. Gentler chemotherapy before stem cell transplant causes long-term remission of follicular lymphoma
9. Genmab Initiates Ofatumumab Phase II Study in Diffuse Large B-Cell Lymphoma
10. Lymphoma drug used to treat skin disorders
11. Firefly genes allow testing of new therapy against lymphoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/20/2017)... (PRWEB) , ... September 20, 2017 , ... “Finn Mouseson”: ... take precedence in an average life. This mouse sets out on a journey that ... heart. “Finn Mouseson” is the creation of newly published author and illustrator, Melody Gersonde-Mickelson, ...
(Date:9/20/2017)... ... ... “The Financial Favor of God; Second Edition”: a personal and exquisite recipe ... creation of published author, Brooks Rathell. , “We typically hear about the favor of ... financial favor of God. Not only does it exist, but it is meant for ...
(Date:9/19/2017)... ... September 19, 2017 , ... DeSola Group, ... marketing leader, Denise Flannery, to its strategic advisory and client development team. ... will work with clients across different industries to develop and implement market-justified strategies, ...
(Date:9/19/2017)... ... 2017 , ... The Lymphoma Research Foundation (LRF) – the ... the lymphoma community through a comprehensive series of education programs, outreach initiatives and ... Swirl: A Wine Tasting Event series on Thursday, October 26, 2017. Hosted at ...
(Date:9/19/2017)... MD (PRWEB) , ... September 19, 2017 , ... ... the Society of Professional Benefit Administrators (SPBA) hosted “Expanding Your Success” ... for SPBA Members as it focused on best practices for third party administrators ...
Breaking Medicine News(10 mins):
(Date:9/12/2017)... 12, 2017  ValGenesis Inc., the global leader ... pleased to announce the appointment of Dr. ... Board of Directors and Chairman of Advisory Board ... science companies to manage their entire validation lifecycle ... in this process. Furthermore, ValGenesis VLMS enables rigorous ...
(Date:9/9/2017)... Sept. 9, 2017  Eli Lilly and Company (NYSE: ... secondary endpoint data for lasmiditan, an investigational, oral, first-in-class ... statistically significant improvements compared to placebo in the Phase ... at the 18th Congress of the International Headache Society ... "The data presented today demonstrate lasmiditan,s potential to reduce ...
(Date:9/7/2017)... 7, 2017 Caris Life Sciences, a ... the promise of precision medicine, today announced results ... of its molecular profiling approach in guiding therapeutic ... profiling plus (CGP+) with Caris Molecular Intelligence ® ... a molecular level, leading to more therapeutic options ...
Breaking Medicine Technology: